Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,370,899
  • Shares Outstanding, K 42,742
  • Annual Sales, $ 421,030 K
  • Annual Income, $ -11,020 K
  • 60-Month Beta 1.22
  • Price/Sales 5.51
  • Price/Cash Flow 31.45
  • Price/Book 5.89
Trade PCRX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.45
  • Number of Estimates 7
  • High Estimate 0.54
  • Low Estimate 0.33
  • Prior Year 0.26
  • Growth Rate Est. (year over year) +73.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.58 +5.50%
on 10/20/20
61.35 -9.58%
on 10/01/20
-3.47 (-5.89%)
since 09/23/20
3-Month
51.48 +7.75%
on 07/28/20
64.44 -13.92%
on 08/19/20
+1.60 (+2.97%)
since 07/23/20
52-Week
27.46 +102.00%
on 03/23/20
64.44 -13.92%
on 08/19/20
+16.17 (+41.15%)
since 10/23/19

Most Recent Stories

More News
Pacira Launches State-of-the-Art Training Center Dedicated to Advancing Best Practice Regional Approaches to Manage Acute Pain

--The Pacira Innovation and Training Center of Tampa will provide clinicians with a flexible environment for hands-on learning--

PCRX : 55.47 (+2.14%)
Pacira BioSciences (PCRX) Enters Oversold Territory

Pacira BioSciences (PCRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

PCRX : 55.47 (+2.14%)
Pacira to Report Third Quarter 2020 Financial Results on Thursday October 29, 2020

Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, October 29, 2020. Following the release,...

PCRX : 55.47 (+2.14%)
Is Pacira BioSciences (PCRX) Outperforming Other Medical Stocks This Year?

Is (PCRX) Outperforming Other Medical Stocks This Year?

PCRX : 55.47 (+2.14%)
Pacira BioSciences Reports Preliminary Net Product Sales of $116.9 Million for the Third Quarter of 2020

-- EXPAREL average daily sales at 110% of the prior year for the third quarter and 110% of the prior year for the month of September --

PCRX : 55.47 (+2.14%)
Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU

The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

IRWD : 9.64 (+1.58%)
PCRX : 55.47 (+2.14%)
INFI : 1.1800 (unch)
ALDX : 7.64 (+0.66%)
Pacira Receives Positive CHMP Opinion for EXPAREL(R) (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain

-- CHMP opinion supported by four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery --

PCRX : 55.47 (+2.14%)
IPG and Pacira BioSciences Announce Collaboration to Reduce Postsurgical Opioid Prescribing and Surgical Procedure Costs

IPG, the industry-leading provider of surgical cost management solutions, and Pacira BioSciences, Inc. (NADSAQ: PCRX), a leading provider of non-opioid pain management options, today announced a collaboration...

PCRX : 55.47 (+2.14%)
Pacira BioSciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference

Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 H.C. Wainwright 22 Annual Global Investment Conference at 3:30 PM ET on Monday, September 14, 2020. Live audio of...

PCRX : 55.47 (+2.14%)
Shares of PCRX Up 74.0% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Pacira Pharmaceu (NASDAQ:PCRX) on April 9th, 2020 at $34.69. In approximately 5 months, Pacira Pharmaceu has returned 73.99% as of today's recent price of $60.35.

PCRX : 55.47 (+2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc....

See More

Key Turning Points

2nd Resistance Point 56.28
1st Resistance Point 55.87
Last Price 55.47
1st Support Level 54.67
2nd Support Level 53.88

See More

52-Week High 64.44
Last Price 55.47
Fibonacci 61.8% 50.31
Fibonacci 50% 45.95
Fibonacci 38.2% 41.59
52-Week Low 27.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar